News & Events about Eyepoint Pharmaceuticals Inc.
EYEPOINT SHAREHOLDER ACTION REMINDER EYEPOINT SHAREHOLDER ACTION REMINDER PR Newswire NEW YORK, Jan. 28, 2023 Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options NEW YORK, Jan. 28...
State-of-the-art cGMP manufacturing facility to be built in Northbridge, Massachusetts Awarded $1.9 million of state and local grants with rent commencing in second half of 2024 WATERTOWN, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical ...
EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who...
EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who...
Topline data for Phase 2 DAVIO 2 clinical trial in wet AMD expected in 4Q 2023 Enrollment remains on-track in Phase 2 DAVIO 2 clinical trial for wet AMD and Phase 2 PAVIA clinical trial for NPDR Full-year 2022 net product revenue estimated to exceed $39.5 million versus $35.3 million in 2021 Cash ...